Treatment of Klebsiella pneumoniae Infections

Introduction to Treatment Options

The International Society for Antimicrobial Chemotherapy recommends ceftazidime/avibactam or meropenem/vaborbactam as first-line treatment options for Klebsiella pneumoniae infections, particularly for carbapenem-resistant strains, with strong recommendation and moderate certainty of evidence 1, 2

For susceptible K. pneumoniae, third and fourth-generation cephalosporins, such as ceftriaxone, cefotaxime, and cefepime, are effective first-line treatments, as recommended by the Infectious Diseases Society of America 3
For ESBL-producing K. pneumoniae, carbapenems, such as meropenem, imipenem-cilastatin, or ertapenem, remain the first-line treatment options, according to the World Health Organization 2
For KPC-producing K. pneumoniae, ceftazidime/avibactam or meropenem/vaborbactam should be used as first-line treatment options, with a conditional recommendation and low certainty of evidence, as suggested by the European Society of Clinical Microbiology and Infectious Diseases 1, 2

For respiratory infections, such as pneumonia, meropenem/vaborbactam may be preferred due to better epithelial lining fluid concentrations, as recommended by the American Thoracic Society 1, 2

Patients with KPC-producing K. pneumoniae bloodstream infections treated with ceftazidime/avibactam had significantly lower 28-day mortality compared to those treated with other active agents, according to a study published in the International Journal of Antimicrobial Agents 1
Meropenem/vaborbactam demonstrated higher clinical cure rates, decreased mortality, and reduced nephrotoxicity compared to best available therapy in the TANGO II study, as reported by the Infectious Diseases Society of America 1

Traditional antibiotic regimens, including colistin, have shown poor efficacy and unfavorable toxicity profiles compared to newer agents, according to the World Health Organization 4
Inappropriate use of carbapenems should be avoided to reduce selective pressure and association with increasing carbapenem-resistant Enterobacteriaceae, as recommended by the Centers for Disease Control and Prevention 5
Tigecycline performs poorly in bacteremic patients and should not be considered first-line therapy in patients with healthcare-associated pneumonia and bacteremia, according to the European Society of Clinical Microbiology and Infectious Diseases 5

Rapid molecular testing should be used to identify specific carbapenemase types to guide appropriate therapy, as recommended by the Infectious Diseases Society of America 2
Susceptibility testing is essential as K. pneumoniae may have variable resistance patterns, according to the Clinical and Laboratory Standards Institute 4
Blood cultures should be repeated to document clearance of bacteremia, as suggested by the American Society for Microbiology 4

ESBL-producing strains remain intrinsically resistant to ampicillin and other aminopenicillins, and these strains acquire resistance to cephalosporins and aztreonam through ESBL production but remain susceptible to carbapenems 6
In Taiwan data, ertapenem susceptibility was 90% for ESBL-producing K. pneumoniae using older breakpoints, dropping to 78% with newer CLSI 2010 breakpoints 7

Ceftazidime/avibactam has resistance rates ranging from 0% to 12.8% in KPC-producing isolates, meaning susceptibility is approximately 87-100% 8
Tigecycline has a susceptibility of approximately 85% (resistance rate 15%), though it performs poorly in bacteremic patients 8

28-day mortality with ceftazidime/avibactam was 18.3% versus 40.8% with other active agents (p=0.005) in KPC-producing K. pneumoniae bloodstream infections 8
30-day clinical success rates were significantly higher with ceftazidime/avibactam compared to carbapenem plus aminoglycoside (p=0.04) or carbapenem plus colistin (p=0.009) 8
Meropenem/vaborbactam demonstrated higher clinical cure rates and decreased mortality compared to best available therapy in the TANGO II study 8

Some KPC-producing strains have MICs within the susceptible range for carbapenems by routine testing but still cause clinical failures when treated with carbapenems 9
Modified Hodge Test (MHT) should be performed on carbapenem-susceptible Enterobacteriaceae with elevated MICs, with sensitivity and specificity exceeding 90% for detecting carbapenemases 9

The American Thoracic Society recommends using carbapenems (meropenem, imipenem, ertapenem) as the reliable first-line choice for ESBL-producing K. pneumoniae 10
The Infectious Diseases Society of America suggests that piperacillin/tazobactam should NOT be used for carbapenem-resistant K. pneumoniae (CRE) 11, 12

For KPC-producing strains, the European Society of Clinical Microbiology and Infectious Diseases recommends ceftazidime/avibactam or meropenem/vaborbactam as first-line options with strong recommendations 11
For MBL-producing strains, the International Society for Antimicrobial Chemotherapy suggests using ceftazidime/avibactam plus aztreonam or cefiderocol 12
The Centers for Disease Control and Prevention documented a carbapenem-resistant K. pneumoniae isolate that remained resistant despite piperacillin/tazobactam therapy, requiring colistin and ultimately showing susceptibility only to tigecycline, colistin, and polymyxin B 13

Rapid molecular testing should identify specific carbapenemase types (KPC, MBL, OXA-48) to guide therapy, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 11
The American College of Chest Physicians advises against using piperacillin/tazobactam for empiric therapy in settings with high ESBL or CRE prevalence (>10% resistance rates) without rapid diagnostic confirmation of susceptibility 11